Mechanism of action
Gelatin solutions function as colloid plasma volume expanders by increasing the oncotic (colloid osmotic) pressure of the intravascular compartment. The large gelatin polypeptide molecules (molecular weight 30,000–35,000 Da) are too large to readily cross capillary membranes under normal physiological conditions.
By remaining in the intravascular space, gelatin exerts oncotic pressure that retains water within blood vessels and draws interstitial fluid back into the circulation. This mechanism rapidly expands plasma volume, improving preload, cardiac output, and tissue perfusion in hypovolemic states.
Gelatin is produced by thermal degradation and hydrolysis of bovine collagen. Two main formulations exist: succinylated gelatin (modified fluid gelatin) and polygeline (urea-linked gelatin). The succinylation or cross-linking process increases molecular stability and reduces antigenicity, though anaphylactoid reactions remain more common than with crystalloids.
The volume expansion effect is proportional to the infused volume, with initial expansion of approximately 70–80% of the infused volume and a duration of effect of 3–4 hours as the molecules are gradually cleared by renal filtration and reticuloendothelial metabolism.
- Gelatin is a colloid plasma expander derived from bovine collagen that increases intravascular oncotic pressure.
- Gelatin carries a higher risk of anaphylactoid reactions (1-3%) compared to crystalloids and albumin.
- Gelatin may cause dilutional coagulopathy and impair platelet function, especially with large volumes.
- Modern resuscitation guidelines favor balanced crystalloids over colloids (including gelatin) for septic shock due to lower AKI risk.
- Gelatin expands plasma volume by ~70-80% of infused volume with a duration of 3-4 hours.
- Gelatin is contraindicated in severe hypervolemia, congestive heart failure, and known hypersensitivity.
- Gelatin does not carry oxygen and is not a substitute for blood transfusion in anemic patients.
- Large trials (SAFE, CRISTAL) show no mortality benefit of colloids over crystalloids in critical illness.
Indications
Gelatin solutions are indicated for:
- Acute hypovolemia: Restoration of circulating volume in hemorrhagic shock, traumatic blood loss, or severe dehydration when crystalloids alone are insufficient
- Perioperative fluid management: Intraoperative volume replacement during major surgery with significant blood loss or fluid shifts
- Burn resuscitation: Adjunct to crystalloid therapy in extensive burn injuries (though albumin is often preferred)
- Septic shock: Early resuscitation in distributive shock states, though balanced crystalloids are now first-line in most protocols
- Hypovolemic shock: Bridge therapy while preparing blood products in massive hemorrhage
Gelatin is used when rapid volume expansion is needed and crystalloid resuscitation has been inadequate or would require excessively large volumes. However, modern resuscitation guidelines increasingly favor balanced crystalloids as first-line therapy due to safety concerns with colloids.
Gelatin does not carry oxygen and does not replace the need for blood transfusion in anemic patients. It is a temporizing measure for volume support, not a substitute for packed red blood cells when oxygen-carrying capacity must be restored.
Pharmacokinetics
Onset and duration: Intravenous gelatin produces immediate plasma volume expansion within minutes of infusion. The peak effect occurs during the infusion itself. The intravascular half-life is 2–4 hours, after which volume expansion gradually diminishes as gelatin molecules are eliminated.
Distribution: Gelatin remains predominantly in the intravascular compartment due to its large molecular size. Approximately 20–30% may leak into the interstitial space over several hours, particularly in conditions of increased capillary permeability (sepsis, inflammation, ischemia-reperfusion injury).
Metabolism and excretion: Gelatin polypeptides are metabolized by proteolytic enzymes and cleared by renal filtration and reticuloendothelial system uptake. Smaller peptide fragments are filtered by the glomerulus and excreted in urine. Complete elimination typically occurs within 24 hours in patients with normal renal function.
Renal impairment: Clearance is prolonged in renal dysfunction, but dose adjustment is generally not required for short-term use. Accumulation with repeated dosing may occur in severe renal failure.
Volume effect: Gelatin expands plasma volume by approximately 70–80% of the infused volume initially. This is less than albumin (100% efficacy) but greater than crystalloids (20–25% efficacy).
Adverse effects
Common adverse effects
- Anaphylactoid reactions: Histamine release causing flushing, urticaria, pruritus, bronchospasm, hypotension (1–3% incidence, higher than crystalloids and albumin)
- Coagulopathy: Dilutional thrombocytopenia and impaired platelet function with large volumes; gelatin may also interfere with fibrin polymerization
- Hypervolemia: Fluid overload, pulmonary edema, worsening heart failure if administered too rapidly or in excess
- Electrolyte disturbances: Hyperchloremic metabolic acidosis (especially with unbalanced formulations), hypernatremia
Serious adverse effects
- Anaphylaxis: True IgE-mediated anaphylaxis is rare but life-threatening; presents with severe hypotension, angioedema, cardiovascular collapse
- Acute kidney injury: Colloid-associated nephrotoxicity, particularly in sepsis and critical illness; mechanism involves tubular injury and inflammatory activation
- Increased bleeding risk: Coagulation factor dilution and platelet dysfunction may exacerbate surgical or traumatic hemorrhage
- Transmission of prions: Theoretical risk from bovine-derived products (Creutzfeldt-Jakob disease), though modern manufacturing minimizes this
Monitoring
Monitor hemodynamic parameters (blood pressure, heart rate, central venous pressure), urine output, electrolytes, renal function, coagulation profile (PT, aPTT, platelet count), and signs of fluid overload or allergic reactions during and after infusion.
Pre-existing coagulopathy or thrombocytopenia may be worsened by gelatin administration.
Contraindications and warnings
Absolute contraindications
- Known hypersensitivity to gelatin or any component of the formulation
- Severe hypervolemia or fluid overload states
- Severe hypernatremia or hyperchloremia
- Severe congestive heart failure (decompensated) where volume expansion may precipitate pulmonary edema
Relative contraindications and warnings
- Coagulopathy or active bleeding: May worsen dilutional coagulopathy and impair hemostasis; use with caution and correct coagulation deficits
- Renal impairment: Risk of accumulation and acute kidney injury; modern evidence suggests colloids may worsen renal outcomes in critically ill patients
- Sepsis and septic shock: Some studies associate gelatin with increased mortality and AKI compared to crystalloids; current guidelines recommend crystalloids first-line
- Head trauma or elevated intracranial pressure: Theoretical concern for worsening cerebral edema, though evidence is limited
- Pulmonary edema: Pre-existing or risk of acute respiratory distress syndrome (ARDS)
Pregnancy and lactation
Gelatin is pregnancy category C (US classification, now replaced by narrative statements). Use only if potential benefit justifies the risk to the fetus. There is limited data on excretion into breast milk; clinical judgment is required.
Special populations
Elderly patients and those with cardiovascular or renal disease are at higher risk for fluid overload and adverse effects. Infuse slowly and monitor closely.
Drug interactions
Gelatin has relatively few direct pharmacokinetic drug interactions, but important pharmacodynamic considerations exist:
Anticoagulants and antiplatelets: Gelatin may potentiate bleeding risk in patients receiving warfarin, heparin, direct oral anticoagulants (DOACs), aspirin, or P2Y12 inhibitors due to dilutional coagulopathy and platelet dysfunction. Monitor coagulation parameters closely.
Nephrotoxic agents: Concurrent use with aminoglycosides, vancomycin, NSAIDs, or other nephrotoxic drugs may increase the risk of acute kidney injury, particularly in critically ill or septic patients.
Diuretics: Loop diuretics (furosemide) and other diuretics may have reduced efficacy due to intravascular volume expansion by gelatin, requiring dose adjustment.
Blood products: Gelatin should not be mixed with blood products in the same intravenous line due to potential incompatibility. Use separate lines or flush between infusions.
Vasopressors and inotropes: Gelatin is often co-administered with norepinephrine, epinephrine, dopamine, or dobutamine in shock states. Volume expansion with gelatin may reduce vasopressor requirements, but hemodynamic monitoring is essential.
Calcium-containing solutions: Gelatin solutions containing calcium may precipitate if mixed with citrated blood products or certain antibiotics (ceftriaxone). Use caution and separate administration.
No significant cytochrome P450 interactions have been reported. Gelatin does not alter the pharmacokinetics of most drugs, though hemodilution may transiently reduce plasma concentrations of drugs with small volumes of distribution.
Clinical pearls
- Crystalloid vs. colloid debate: Large randomized trials (SAFE, CRISTAL, CHEST) show no mortality benefit of colloids over crystalloids in most settings, with some evidence of harm (renal injury, coagulopathy). Balanced crystalloids are now first-line for resuscitation in most protocols.
- Anaphylactoid reactions are more common with gelatin than with albumin or hydroxyethyl starch. Have epinephrine and resuscitation equipment ready during infusion.
- Coagulation effects: Gelatin impairs clot strength and platelet function more than crystalloids. Avoid large volumes in actively bleeding patients or those with pre-existing coagulopathy. Consider thromboelastography (TEG/ROTEM) to guide management.
- Renal safety: Meta-analyses suggest colloids, including gelatin, may increase AKI risk in septic and critically ill patients compared to crystalloids. Current Surviving Sepsis Campaign guidelines recommend crystalloids over colloids for septic shock resuscitation.
- Volume expansion efficiency: Gelatin is more efficient than crystalloids (requires less volume to achieve same hemodynamic effect) but less efficient than albumin. This may be relevant when minimizing total fluid administration is a goal (e.g., ARDS, abdominal compartment syndrome).
- Cost considerations: Gelatin is significantly less expensive than albumin but more expensive than crystalloids. Cost-effectiveness analyses generally favor crystalloid-first strategies.
- Bovine origin: Derived from cow collagen; theoretical prion transmission risk led to reduced use in some countries. Modern manufacturing with acid hydrolysis and nanofiltration minimizes this risk.
- Gelatin vs. hydroxyethyl starch (HES): HES is associated with higher rates of AKI and mortality in sepsis and is now contraindicated in critically ill patients in many jurisdictions. Gelatin has a better safety profile than HES but still inferior to crystalloids in most scenarios.
- Not a blood substitute: Gelatin does not carry oxygen, provide clotting factors, or replace red cell mass. Transfuse blood products when hemoglobin is critically low or coagulopathy is present.
Practice questions
1. A 45-year-old man is brought to the emergency department following a motor vehicle collision with an estimated 1500 mL blood loss. He is hypotensive (BP 85/50 mmHg) and tachycardic (HR 120/min). After initial crystalloid resuscitation, the trauma team decides to administer gelatin solution for further volume expansion. Thirty minutes after starting the gelatin infusion, the patient develops diffuse urticaria, wheezing, and his blood pressure drops to 70/40 mmHg. Which of the following is the most likely mechanism of this reaction?
2. A 62-year-old woman undergoes major abdominal surgery with significant intraoperative blood loss. She receives 2 liters of gelatin solution in addition to crystalloids and packed red blood cells. Postoperatively, laboratory studies show: Hemoglobin 9.2 g/dL, Platelet count 95,000/mm³ (preoperative: 220,000/mm³), PT 16 seconds (normal 11-13), aPTT 42 seconds (normal 25-35), Fibrinogen 180 mg/dL (normal 200-400). Which of the following best explains these coagulation abnormalities?
3. A 55-year-old man with septic shock from pneumonia is admitted to the ICU. Initial management includes broad-spectrum antibiotics and norepinephrine infusion. The intensivist is considering fluid resuscitation options. Based on current evidence from large randomized controlled trials (SAFE, CRISTAL, CHEST), which of the following statements regarding gelatin versus crystalloid resuscitation in septic shock is most accurate?
Frequently asked questions
How does gelatin work as a plasma expander?
Gelatin works by increasing intravascular oncotic (colloid osmotic) pressure. The large gelatin polypeptide molecules (MW 30,000-35,000 Da) remain in blood vessels and draw interstitial fluid back into the circulation, rapidly expanding plasma volume and improving cardiac preload and tissue perfusion. The volume expansion effect is approximately 70-80% of the infused volume initially, with effects lasting 3-4 hours before gradual renal clearance and metabolism.
What are the side effects of gelatin infusion?
Common side effects include anaphylactoid reactions (flushing, urticaria, bronchospasm, hypotension in 1-3% of patients), dilutional coagulopathy with large volumes, and fluid overload causing pulmonary edema. Serious adverse effects include true anaphylaxis, acute kidney injury (especially in septic patients), increased bleeding risk due to platelet dysfunction and coagulation factor dilution, and hyperchloremic metabolic acidosis. Gelatin has higher allergic reaction rates than crystalloids or albumin.
Is gelatin better than normal saline for resuscitation?
Current evidence does not support gelatin superiority over crystalloids for most resuscitation scenarios. Large randomized trials (SAFE, CRISTAL, CHEST) show no mortality benefit of colloids over crystalloids, and some studies suggest gelatin may increase acute kidney injury risk in septic and critically ill patients. Balanced crystalloids are now first-line in most resuscitation protocols. Gelatin requires smaller volumes to achieve hemodynamic goals but carries higher risks of allergic reactions and coagulopathy.
When is gelatin contraindicated?
Gelatin is absolutely contraindicated in patients with known hypersensitivity to gelatin, severe hypervolemia or fluid overload, decompensated congestive heart failure, and severe hypernatremia or hyperchloremia. Relative contraindications include active coagulopathy or bleeding (may worsen dilutional coagulopathy), severe renal impairment, septic shock (crystalloids preferred), and pulmonary edema or ARDS. Use caution in elderly patients and those with cardiovascular or renal disease due to increased risk of fluid overload.
Gelatin vs albumin — what is the difference?
Both are colloid plasma expanders, but albumin is a human-derived protein while gelatin is semi-synthetic from bovine collagen. Albumin provides 100% volume expansion per liter infused versus 70-80% for gelatin, and has a longer intravascular half-life (16-24 hours vs. 3-4 hours). Gelatin has higher rates of anaphylactoid reactions (1-3%) compared to albumin (<0.1%). Albumin is significantly more expensive. Neither shows mortality benefit over crystalloids in large trials, but albumin may be preferred in specific settings like hepatic failure or burns.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: B05AA06
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.